Quoin's QRX003 wins EMA Orphan Drug Designation for Peeling Skin Syndrome

Quoin Pharmaceuticals, Ltd.

• EMA granted Orphan Drug Designation to lead candidate QRX003 for Peeling Skin Syndrome on Oct 14, 2026, giving 10 years of EU market exclusivity if approved.
• Quoin says it is on track to initiate the first-ever formal clinical study in Peeling Skin Syndrome before year end.
• Designation is the eighth regulatory milestone for QRX003, which also holds US FDA Pediatric Rare Disease and Fast Track designations for the indication.
• QRX003 also has Orphan Drug Designation in the US, Europe and Japan for Netherton Syndrome, where it is in late-stage trials and no therapies are approved.